Intelligence · Clinical Development
Pipeline search results
Programs matching “monotherapy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 14 pipeline programs matching "monotherapy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Capecitabine monotherapy
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Start antiplatelet monotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Intracerebral Hemorrhage
1 trial -
UC-IMM-2101
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
D798MC00002
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
Genomically Directed Monotherapy
Vera Therapeutics
Malignant Neoplasm of Breast
1 trial -
SKB103 for injection monotherapy
Sichuan Provincial People's Hospital
Advanced Solid Tumors
1 trial -
Selpercatinib Monotherapy
United Therapeutics Europe Ltd
Differentiated Thyroid Cancer
1 trial -
Venetoclax monotherapy
Adaptive Biotechnologies Corp
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Volrustomig
AstraZeneca
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
1 trial -
cemiplimab (monotherapy)
Regeneron UK Limited
Relapsed Solid Tumor
1 trial -
silevertinib (BDTX-1535) monotherapy
Blackmores Limited
Non-Small Cell Lung Cancer
1 trial -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
1 trial -
P2Y12 antagonist monotherapy
Vera Therapeutics
Coronary Artery Disease
1 trial -
Ticagrelor monotherapy
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.